Despite toxicity concerns for CD47 targets in 2023, the macrophage community understands the critical importance of advancing revolutionary treatments for oncology, autoimmunity, inflammation, neurodegenerative disorders, and beyond, making this work more vital than ever

With that, the 6th Macrophage-Directed Therapies Summit will return to Boston this year, uniting biopharma and academia leaders across R&D, Discovery, Biology, Translational, and Clinical Development to confront the most pressing challenges in the space, with crucial discussions on the current investment landscape, giving you the information needed to secure strategic partnerships and navigate the evolving funding environment.

This is your chance to gain first-hand knowledge and network with top institutions like Carisma Therapeutics, Resolution Therapeutics, Harvard Medical School, and Johns Hopkins School of Medicine, as they unravel the latest discoveries in macrophage biology and drive us closer to proof-of-concept data.